For the year ended 31 December 2025
Note | 2025 | 2024 | |
|---|---|---|---|
Revenue | 3 | ||
Cost of sales | ( | ( | |
Gross profit | |||
Distribution costs | ( | ( | |
Administrative expenses | ( | ( | |
Exceptional costs of closure of business | 5 | ( | ( |
Operating profit | 5 | ||
Adjusted operating profit* | |||
Finance costs | 7 | ( | ( |
Finance income | 7 | ||
Share of profit from joint venture | 10 | ||
Profit before income tax | |||
Adjusted profit before income tax* | |||
Income tax credit/(expense) | 8 | ( | |
Profit/(loss) for the year | ( | ||
Adjusted profit for the year* | |||
Profit/(loss) attributable to: | |||
Equity holders of the Company | ( | ||
| |||
Earnings/(loss) per share: | |||
Basic (p) | 9 | ( | |
Diluted (p) | 9 | ( | |
Adjusted earnings per share** | |||
Basic (p) | 9 | ||
Diluted (p) | 9 |
* This is not an IFRS measure. Adjusted operating profit, profit before tax and profit for the year have been calculated by excluding the exceptional item relating to MuCell closure, amortisation of intangible assets arising on acquisition of subsidiary and exceptional tax credit. See the alternative performance measures for further details. The prior year adjusted profit for the year has been restated to add back the amortisation of acquired intangible assets in MuCell.
** This is not an IFRS measure and has been calculated using the adjusted profit for the year, see the alternative performance measures for further details.
All activities of the Group are continuing. In the prior year the exceptional closure cost relates to the MuCell business, primarily the impairment of tangible and intangible fixed assets.
The notes to the accounts form an integral part of these financial statements.
The Company has elected to take the exemption under Section 408 of the Companies Act 2006 from presenting the Company income statement and other comprehensive income statement.
Company number: 2714645